Drugs / BEN301
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07527936 | Apr 2026 → Aug 2028 | Sjogren syndrome, idiopathic inflammatory myopathy, rheumatoid arthritis, systemic sclerosis | RenJi Hospital | Suspended | No outcome recorded |
| Phase 0 | NCT07502859 | Mar 2026 → Feb 2029 expected | — | Beijing Boren Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BEN301 | “Preclinical studies have shown that BEN301 Injection not only effectively suppresses the aberrant activation of T and B cells in SLE models, but also significantly reduces...” NCT07527936 ↗1“A Study of BEN301 Injection in the Treatment of Autoimmune Diseases” NCT07502859 ↗ |
| Known as | BEN301 Injection | “A Study of BEN301 Injection in the Treatment of Autoimmune Diseases” NCT07502859 ↗ |